Healthcare Industry News: TELCYTA
News Release - September 25, 2006
Telik Updates ASSIST-1 StatusPALO ALTO, Calif., Sept. 25 (HSMN NewsFeed) -- Telik, Inc. (Nasdaq: TELK ) announced today that the pre-specified number of events have been reached on the ASSIST-1 Phase 3 trial in platinum refractory or resistant ovarian cancer.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidate is TELCYTA®, a tumor-activated small molecule product candidate. TELCYTA is in four Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. A second development candidate, TELINTRA(TM), is in clinical development in myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.